

Jun Pang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7193019/publications.pdf>

Version: 2024-02-01

59
papers

1,158
citations

430874

18
h-index

414414

32
g-index

61
all docs

61
docs citations

61
times ranked

2106
citing authors

#	ARTICLE	IF	CITATIONS
1	Whole-genome and Transcriptome Sequencing of Prostate Cancer Identify New Genetic Alterations Driving Disease Progression. <i>European Urology</i> , 2018, 73, 322-339.	1.9	130
2	Profiling Protein Markers Associated with Lymph Node Metastasis in Prostate Cancer by DIGE-based Proteomics Analysis. <i>Journal of Proteome Research</i> , 2010, 9, 216-226.	3.7	92
3	Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells. <i>Journal of Controlled Release</i> , 2010, 147, 278-288.	9.9	74
4	Associations of Mental Health and Personal Preventive Measure Compliance With Exposure to COVID-19 Information During Work Resumption Following the COVID-19 Outbreak in China: Cross-Sectional Survey Study. <i>Journal of Medical Internet Research</i> , 2020, 22, e22596.	4.3	63
5	Expression profiling identifies new function of collapsin response mediator protein 4 as a metastasis-suppressor in prostate cancer. <i>Oncogene</i> , 2010, 29, 4555-4566.	5.9	55
6	Screening of pH-responsive long-circulating polysaccharide-drug conjugate nanocarriers for antitumor applications. <i>Journal of Materials Chemistry B</i> , 2019, 7, 251-264.	5.8	42
7	Prostate stem cell antigen-targeted nanoparticles with dual functional properties: in vivo imaging and cancer chemotherapy. <i>International Journal of Nanomedicine</i> , 2012, 7, 4037.	6.7	40
8	Revealing the prognostic landscape of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: a meta-analysis. <i>Prostate Cancer and Prostatic Diseases</i> , 2020, 23, 220-231.	3.9	39
9	Manipulation of prostate cancer metastasis by locus-specific modification of the CRMP4 promoter region using chimeric TALE DNA methyltransferase and demethylase. <i>Oncotarget</i> , 2015, 6, 10030-10044.	1.8	35
10	Toll-like receptor 9 agonists promote IL-8 and TGF- β 1 production via activation of nuclear factor κ B in PC-3 cells. <i>Cancer Genetics and Cytogenetics</i> , 2009, 192, 60-67.	1.0	34
11	<i>ERG</i> Rearrangement for Predicting Subsequent Cancer Diagnosis in High-Grade Prostatic Intraepithelial Neoplasia and Lymph Node Metastasis. <i>Clinical Cancer Research</i> , 2012, 18, 4163-4172.	7.0	34
12	Nanoparticle Therapy for Prostate Cancer: Overview and Perspectives. <i>Current Topics in Medicinal Chemistry</i> , 2019, 19, 57-73.	2.1	33
13	Toll-like receptor 9 agonists up-regulates the expression of cyclooxygenase-2 via activation of NF- κ B in prostate cancer cells. <i>Molecular Biology Reports</i> , 2010, 37, 1849-1855.	2.3	30
14	Cyclooxygenase-2 Expression Is Associated with Vascular Endothelial Growth Factor-C and Lymph Node Metastases in Human Prostate Cancer. <i>Archives of Medical Research</i> , 2009, 40, 268-275.	3.3	28
15	Detection of TMPRSS2-ETS Fusions by a Multiprobe Fluorescence in Situ Hybridization Assay for the Early Diagnosis of Prostate Cancer. <i>Journal of Molecular Diagnostics</i> , 2010, 12, 718-724.	2.8	25
16	Synthesis, characterization and osteoconductivity properties of bone fillers based on alendronate-loaded poly(μ -caprolactone)/hydroxyapatite microspheres. <i>Journal of Materials Science: Materials in Medicine</i> , 2011, 22, 547-555.	3.6	25
17	Subrenal capsule grafting technology in human cancer modeling and translational cancer research. <i>Differentiation</i> , 2016, 91, 15-19.	1.9	24
18	A Meta-Analysis of Glasgow Prognostic Score and Modified Glasgow Prognostic Score as Biomarkers for Predicting Survival Outcome in Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2020, 10, 1541.	2.8	24

#	ARTICLE	IF	CITATIONS
19	Reactive oxygen species and glutathione dual responsive nanoparticles for enhanced prostate cancer therapy. <i>Materials Science and Engineering C</i> , 2021, 123, 111956.	7.3	21
20	Bidirectional Interaction Between Cancer Cells and Platelets Provides Potential Strategies for Cancer Therapies. <i>Frontiers in Oncology</i> , 2021, 11, 764119.	2.8	20
21	CRISPR screening identifies CDK12 as a conservative vulnerability of prostate cancer. <i>Cell Death and Disease</i> , 2021, 12, 740.	6.3	19
22	Mutated SPOP E3 Ligase Promotes 17 β HSD4 Protein Degradation to Drive Androgenesis and Prostate Cancer Progression. <i>Cancer Research</i> , 2021, 81, 3593-3606.	0.9	18
23	Calpain α 2 triggers prostate cancer metastasis via enhancing CRMP4 promoter methylation through NF κ B/DNMT1 signaling pathway. <i>Prostate</i> , 2018, 78, 682-690.	2.3	15
24	Dendritic cells transduced with a PSMA-encoding adenovirus and cocultured with autologous cytokine-induced lymphocytes induce a specific and strong immune response against prostate cancer cells. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2009, 27, 26-32.	1.6	14
25	Single-port transvesical laparoscopic radical prostatectomy for organ-confined prostate cancer: technique and outcomes. <i>BJU International</i> , 2013, 112, 944-952.	2.5	14
26	Cyclin-dependent kinase 7 inhibitor THZ1 in cancer therapy. <i>Chronic Diseases and Translational Medicine</i> , 2019, 5, 155-169.	1.2	14
27	miR-301a Promotes Cell Proliferation by Repressing PTEN in Renal Cell Carcinoma. <i>Cancer Management and Research</i> , 2020, Volume 12, 4309-4320.	1.9	14
28	A polymer-calcium phosphate nanocapsule for RNAi-induced oxidative stress and cascaded chemotherapy. <i>Journal of Controlled Release</i> , 2021, 340, 259-270.	9.9	13
29	Prospective Study of CRMP4 Promoter Methylation in Prostate Biopsies as a Predictor For Lymph Node Metastases. <i>Journal of the National Cancer Institute</i> , 2017, 109, djw282.	6.3	12
30	P110 α Inhibition Reduces Histone H3K4 Di-methylation in Prostate Cancer. <i>Prostate</i> , 2017, 77, 299-308.	2.3	12
31	Association of doublecortin-like kinase 1 with tumor aggressiveness and poor biochemical recurrence-free survival in prostate cancer. <i>OncoTargets and Therapy</i> , 2018, Volume 11, 1077-1086.	2.0	10
32	Fundamentals and applications of nanoparticles for ultrasound-based imaging and therapy. <i>Nano Select</i> , 2020, 1, 263-284.	3.7	9
33	MicroRNA-regulated transcriptome analysis identifies four major subtypes with prognostic and therapeutic implications in prostate cancer. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 4941-4953.	4.1	9
34	Laparoscopic radical prostatectomy plus extended lymph nodes dissection for cases with non-extra node metastatic prostate cancer: 5-year experience in a single Chinese institution. <i>Journal of Cancer Research and Clinical Oncology</i> , 2013, 139, 871-878.	2.5	8
35	Dual pH- and Glutathione-Responsive CO ₂ -Generating Nanodrug Delivery System for Contrast-Enhanced Ultrasonography and Therapy of Prostate Cancer. <i>ACS Applied Materials & Interfaces</i> , 2021, 13, 12899-12911.	8.0	8
36	Associations between polymorphisms in the IL-4 and IL-4 receptor genes and urinary carcinomas: a meta-analysis. <i>International Journal of Clinical and Experimental Medicine</i> , 2015, 8, 1227-33.	1.3	8

#	ARTICLE	IF	CITATIONS
37	Overexpression of PFKFB3 promotes cell glycolysis and proliferation in renal cell carcinoma. <i>BMC Cancer</i> , 2022, 22, 83.	2.6	8
38	Proteomic analysis of rat penile tissue in a model of erectile dysfunction after radical prostatectomy. <i>BJU International</i> , 2007, 99, 1500-1505.	2.5	7
39	Development and validation of a multiparametric MRI-based radiomics signature for distinguishing between indolent and aggressive prostate cancer. <i>British Journal of Radiology</i> , 2022, 95, 20210191.	2.2	7
40	Smart nanocarriers as therapeutic platforms for bladder cancer. <i>Nano Research</i> , 2022, 15, 2157-2176.	10.4	7
41	Circular RNA circVAMP3 promotes aerobic glycolysis and proliferation by regulating LDHA in renal cell carcinoma. <i>Cell Death and Disease</i> , 2022, 13, 443.	6.3	7
42	CDK7 blockade suppresses super-enhancer-associated oncogenes in bladder cancer. <i>Cellular Oncology (Dordrecht)</i> , 2021, 44, 871-887.	4.4	6
43	Systematic Chromatin Accessibility Analysis Based on Different Immunological Subtypes of Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 575425.	2.8	6
44	Combined analysis of CRMP4 methylation levels and CAPRA-S score predicts metastasis and outcomes in prostate cancer patients. <i>Asian Journal of Andrology</i> , 2018, 20, 56.	1.6	6
45	Smart dual responsive nanocarriers with reactive oxygen species amplification assisted synergistic chemotherapy against prostate cancer. <i>Journal of Colloid and Interface Science</i> , 2022, 622, 789-803.	9.4	6
46	Investigation of Optimal Prostate Biopsy Schemes for Chinese Patients with Different Clinical Characteristics. <i>Urologia Internationalis</i> , 2012, 89, 425-432.	1.3	4
47	Laparoscopic Radical Prostatectomy Plus Extended Lymph Node Dissection in Combination With Immediate Androgen Deprivation Therapy for Cases of pT3-4N0-1M0 Prostate Cancer: A Multimodal Study of 8 Years' Follow-up. <i>Clinical Genitourinary Cancer</i> , 2016, 14, e321-e327.	1.9	4
48	Revealing Prognostic Value of Skeletal-Related Parameters in Metastatic Castration-Resistant Prostate Cancer on Overall Survival: A Systematic Review and Meta-Analysis of Randomized Controlled Trial. <i>Frontiers in Oncology</i> , 2020, 10, 586192.	2.8	4
49	Proteomic analysis of rat penile tissue in a model of erectile dysfunction after radical prostatectomy. <i>BJU International</i> , 2007, 99, 1500-1505.	2.5	3
50	ERG rearrangement as a novel marker for predicting the extra-prostatic extension of clinically localised prostate cancer. <i>Oncology Letters</i> , 2016, 11, 2532-2538.	1.8	3
51	Which Way to Choose for the Treatment of Metastatic Prostate Cancer: A Case Report and Literature Review. <i>Frontiers in Oncology</i> , 2021, 11, 659442.	2.8	3
52	Efficacy and safety of Androgen Deprivation Therapy (ADT) combined with modified docetaxel chemotherapy versus ADT combined with standard docetaxel chemotherapy in patients with metastatic castration-resistant prostate cancer: study protocol for a multicentre prospective randomized controlled trial. <i>BMC Cancer</i> , 2022, 22, 177.	2.6	2
53	Enhanced Antitumor Effects by the Coculture of Allotumor RNA-Pulsed Dendritic Cells with Autologous Cytokine-Induced Killer Cells on Hormone-Refractory Prostate Cancer. <i>Cancer Investigation</i> , 2007, 25, 527-534.	1.3	1
54	Collapsin response mediator protein 4 promoter methylation level as a potential predictor for diagnosing primary malignant lymphoma of the prostate. <i>Cancer Cell International</i> , 2018, 18, 3.	4.1	1

#	ARTICLE	IF	CITATIONS
55	The Effect of Single-port Transvesical Laparoscopic Radical Prostatectomy on Erectile Function and Urinary Continence Compared to Intrafascial Endoscopic Extraperitoneal Radical Prostatectomy. <i>Urology Journal</i> , 2020, 17, 592-596.	0.4	1
56	GW24-e3520â€¦...Association of cardiovascular disease and erectile dysfunction: share the same risk factors?. <i>Heart</i> , 2013, 99, A130.2-A130.	2.9	0
57	MP99-04 TRUNCATED-CRMP4 BY CALPAIN-2 SUPPRESSES CRMP4 TO PROMOTE METASTASIS OF PROSTATE CANCER VIA PROMOTER METHYLATION THROUGH E2F1/NF-?B/DNMT1 SIGNALING. <i>Journal of Urology</i> , 2017, 197, .	0.4	0
58	AB201. Two birds with one stone: Î±-blocker therapy on LUTS/BPH in men concomitant with mild hypertension. <i>Translational Andrology and Urology</i> , 2016, 5, AB201-AB201.	1.4	0
59	Prepubertal-type teratoma in a postpubertal patient: case report and review of literature. <i>International Journal of Clinical and Experimental Pathology</i> , 2020, 13, 2407-2411.	0.5	0